BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
pharmaphorum11h
MSD joins PD-1/VEGF push in cancer with LaNova deal
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
scmp.com13h
Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs
In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last year, BioNTech obtained the exclusive global development and ...
BioNTech signs agreement to acquire Biotheus to enhance tumor treatment capabilities
BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...
Mena FN18h
BioNTech purchases Chinese biotechnology company to improve oncology strategy
The German firms is going to obtain the rights to Biotheus’ “investigational bispecific antibody” named the “BNT327/PM8002,” and use it in its oncology strategy. The advanced clinical asset focuses on ...